Concerned about the safety of intravenous abuse with Pain Therapeutics Inc.’s Remoxy (oxycodone extended-release), a US FDA advisory committee on June 26 recommended against approval of the long-acting opioid, citing a desire to avoid the kinds of adverse public health effects that led to the recent withdrawal of Endo Pharmaceuticals Inc.’s Opana ER.
Members of the anesthetic/analgesic drug products and drug safety and risk management panels voted 14-3 that the efficacy, safety and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?